Alphabet spinout Isomorphic Labs has raised $5 billion in its second major funding round within six months, bringing total capital raised since May 2026 to $7.1 billion. The investment was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz, Alphabet, and existing backers. The capital will fund the advancement of its proprietary Isomorphic Drug Design Engine (IsoDDE) and drive its internal drug discovery pipeline toward human clinical trials.

IsoDDE expands beyond the capabilities of AlphaFold 3 to improve predictions of complex drug binding and docking structures. Isomorphic Labs currently maintains commercial drug discovery partnerships with major pharmaceutical firms including Novartis, Eli Lilly, and Johnson & Johnson, though it has not yet advanced a proprietary candidate through approved clinical trials.

The funding follow structural shifts within Alphabet’s AI organization. Demis Hassabis stepped back from daily management at Google DeepMind in August 2026 to serve as Alphabet’s Chief Scientist while remaining CEO of Isomorphic. DeepMind’s original AlphaFold team was disbanded in July 2026, with key talent shifting to Isomorphic Labs to consolidate Alphabet’s commercial biopharma AI efforts.

Why it matters

  • Massive capital consolidation indicates bio-AI startups are entering an expensive clinical-validation phase requiring mega-scale balance sheets.

  • Reorganization of DeepMind’s biology teams signals Alphabet’s intent to monetize protein structure research directly through commercial drug development.

  • Pharma partnerships are shifting from exploratory computational tools toward full end-to-end AI platform integration.

Source: the-decoder.com